Inflitza 25 Softgel Capsule belongs to the group of medicines called protein kinase inhibitors used to treat acute myeloid leukaemia (AML). It is sometimes, also used to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL).
Inflitza 25 Softgel Capsule contains Midostaurin, which works by blocking the action of kinase enzymes in abnormal cells and stops their division and growth. Thereby, it helps prevent the spread of cancer and mast cells.
Inflitza 25 Softgel Capsule may cause certain side effects such as nausea, vomiting, headache, fever, musculoskeletal pain, and upper abdominal pain. Most of these side effects may not require medical attention and resolve gradually over time. Do not be reluctant to talk with your doctor if any of the side effects persist or worsen. Take Inflitza 25 Softgel Capsule as prescribed by your doctor.
Discontinue taking Inflitza 25 Softgel Capsule and inform your physician if you observe any allergic reactions. Inform the doctor about your health condition and medications to rule out any side effects. Do not take Inflitza 25 Softgel Capsule if you are pregnant or breastfeeding. This medicine is not recommended for children as safety and effectiveness have not been established.